NEW YORK (GenomeWeb) – Genomic Expression recently received a €3.7 million ($4.2 million) EU Horizon 2020 grant to advance a urine-based test for bladder cancer.
Over the next three years, the company and selected partners will assess its OneRNA platform to diagnose cancer, select treatment, and measure response and recurrence. The project, dubbed OneRNA4Bladder, is for small- and medium-sized enterprises. Genomic Expression is responsible for contracting out all work associated with it.